Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,298 shares of the biopharmaceutical company’s stock after purchasing an additional 19 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,365,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the last quarter. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $26,000. Sachetta LLC raised its holdings in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at about $28,000. Finally, Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at about $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.7 %

Shares of REGN stock opened at $782.51 on Friday. The company has a market capitalization of $85.99 billion, a price-to-earnings ratio of 19.36, a PEG ratio of 3.10 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $1,000.06 and a 200 day moving average price of $1,035.67. Regeneron Pharmaceuticals, Inc. has a twelve month low of $780.95 and a twelve month high of $1,211.20.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Evercore ISI cut their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Barclays reduced their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Finally, Citigroup started coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday. They issued a “neutral” rating and a $895.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,097.14.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.